Compare Novavax Inc (NVAX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VEA | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | — |
52-Week High | $11.19 | $73.79 |
52-Week Low | $6.22 | $58.90 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
Vanguard FTSE Developed Markets ETF (VEA) trades at $73.46, down 0.41% on the day but near its 52-week high of $74.04. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights increased institutional buying, such as Allianz Asset Management boosting its stake by 11.8% in Q2 2026 (Defense World, 2026-09-09). The ETF offers low-cost exposure to developed international markets, with an expense ratio of 0.03% (The Motley Fool, 2026-08-20).
VEA's outlook is supported by institutional accumulation and cost efficiency, but risks include concentration in developed markets missing emerging growth. Proximity to the 52-week high suggests limited near-term upside without broader international market momentum. Investors benefit from diversification outside the U.S., though currency fluctuations and geopolitical events pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
